Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia.

Literature DB >> 25239264

Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia.

Manja Meggendorfer¹, Torsten Haferlach², Tamara Alpermann², Sabine Jeromin², Claudia Haferlach², Wolfgang Kern², Susanne Schnittger².

Abstract

Entities: Disease Gene

Keywords: aCML; chronic myelomonocytic leukemia; chronic neutrophilic leukemia; molecular pattern

Mesh：

Substances：
Biomarkers, Tumor

Year: 2014 PMID： 25239264 PMCID： PMC4258749 DOI： 10.3324/haematol.2014.113159

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

14 in total

1. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.

Authors: Alexander Kohlmann; Vera Grossmann; Hans-Ulrich Klein; Sonja Schindela; Tamara Weiss; Beray Kazak; Frank Dicker; Susanne Schnittger; Martin Dugas; Wolfgang Kern; Claudia Haferlach; Torsten Haferlach
Journal: J Clin Oncol Date: 2010-07-19 Impact factor: 44.544

2. Molecular basis of myelodysplastic/myeloproliferative neoplasms.

Authors: Andreas Reiter; Rosangela Invernizzi; Nicholas C P Cross; Mario Cazzola
Journal: Haematologica Date: 2009-12 Impact factor: 9.941

3. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.

Authors: Felicitas Thol; Inna Friesen; Frederik Damm; Haiyang Yun; Eva M Weissinger; Jürgen Krauter; Katharina Wagner; Anuhar Chaturvedi; Amit Sharma; Martin Wichmann; Gudrun Göhring; Christiane Schumann; Gesine Bug; Oliver Ottmann; Wolf-Karsten Hofmann; Brigitte Schlegelberger; Michael Heuser; Arnold Ganser
Journal: J Clin Oncol Date: 2011-05-16 Impact factor: 44.544

4. Frequent pathway mutations of splicing machinery in myelodysplasia.

Authors: Kenichi Yoshida; Masashi Sanada; Yuichi Shiraishi; Daniel Nowak; Yasunobu Nagata; Ryo Yamamoto; Yusuke Sato; Aiko Sato-Otsubo; Ayana Kon; Masao Nagasaki; George Chalkidis; Yutaka Suzuki; Masashi Shiosaka; Ryoichiro Kawahata; Tomoyuki Yamaguchi; Makoto Otsu; Naoshi Obara; Mamiko Sakata-Yanagimoto; Ken Ishiyama; Hiraku Mori; Florian Nolte; Wolf-Karsten Hofmann; Shuichi Miyawaki; Sumio Sugano; Claudia Haferlach; H Phillip Koeffler; Lee-Yung Shih; Torsten Haferlach; Shigeru Chiba; Hiromitsu Nakauchi; Satoru Miyano; Seishi Ogawa
Journal: Nature Date: 2011-09-11 Impact factor: 49.962

5. Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information.

Authors: Ulrike Bacher; Torsten Haferlach; Wolfgang Kern; Wolfgang Hiddemann; Susanne Schnittger; Claudia Schoch
Journal: Ann Hematol Date: 2005-02-04 Impact factor: 3.673

6. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.

Authors: Rocco Piazza; Simona Valletta; Nils Winkelmann; Sara Redaelli; Roberta Spinelli; Alessandra Pirola; Laura Antolini; Luca Mologni; Carla Donadoni; Elli Papaemmanuil; Susanne Schnittger; Dong-Wook Kim; Jacqueline Boultwood; Fabio Rossi; Giuseppe Gaipa; Greta P De Martini; Paola Francia di Celle; Hyun Gyung Jang; Valeria Fantin; Graham R Bignell; Vera Magistroni; Torsten Haferlach; Enrico Maria Pogliani; Peter J Campbell; Andrew J Chase; William J Tapper; Nicholas C P Cross; Carlo Gambacorti-Passerini
Journal: Nat Genet Date: 2012-12-09 Impact factor: 38.330

Review 7. The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment.

Authors: Jason Gotlib; Julia E Maxson; Tracy I George; Jeffrey W Tyner
Journal: Blood Date: 2013-07-29 Impact factor: 22.113

8. Prognostic score including gene mutations in chronic myelomonocytic leukemia.

Authors: Raphaël Itzykson; Olivier Kosmider; Aline Renneville; Véronique Gelsi-Boyer; Manja Meggendorfer; Margot Morabito; Céline Berthon; Lionel Adès; Pierre Fenaux; Odile Beyne-Rauzy; Norbert Vey; Thorsten Braun; Torsten Haferlach; François Dreyfus; Nicholas C P Cross; Claude Preudhomme; Olivier A Bernard; Michaela Fontenay; William Vainchenker; Susanne Schnittger; Daniel Birnbaum; Nathalie Droin; Eric Solary
Journal: J Clin Oncol Date: 2013-05-20 Impact factor: 44.544

9. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.

Authors: Julia E Maxson; Jason Gotlib; Daniel A Pollyea; Angela G Fleischman; Anupriya Agarwal; Christopher A Eide; Daniel Bottomly; Beth Wilmot; Shannon K McWeeney; Cristina E Tognon; J Blake Pond; Robert H Collins; Basem Goueli; Stephen T Oh; Michael W Deininger; Bill H Chang; Marc M Loriaux; Brian J Druker; Jeffrey W Tyner
Journal: N Engl J Med Date: 2013-05-09 Impact factor: 91.245

Review 10. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.

Authors: Véronique Gelsi-Boyer; Mandy Brecqueville; Raynier Devillier; Anne Murati; Marie-Joelle Mozziconacci; Daniel Birnbaum
Journal: J Hematol Oncol Date: 2012-03-21 Impact factor: 17.388

33 in total

1. Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.

Authors: Constance Baer; Wolfgang Kern; Sarah Koch; Niroshan Nadarajah; Sonja Schindela; Manja Meggendorfer; Claudia Haferlach; Torsten Haferlach
Journal: Haematologica Date: 2016-04-21 Impact factor: 9.941

2. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia.

Authors: Mrinal M Patnaik; Daniela Barraco; Terra L Lasho; Christy M Finke; Kaaren Reichard; Katherine P Hoversten; Rhett P Ketterling; Naseema Gangat; Ayalew Tefferi
Journal: Am J Hematol Date: 2017-04-29 Impact factor: 10.047

3. Aberrations identified by genomic arrays in normal karyotype CMML can be detected in 40% of patients, but do not add prognostic information to molecular mutations.

Authors: C Vetro; C Haferlach; T Haferlach; M Zenger; N Nadarajah; W Kern; M Meggendorfer
Journal: Leukemia Date: 2016-05-25 Impact factor: 11.528

Review 4. Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing.

Authors: Zhuang Zuo; Shaoying Li; Jie Xu; M James You; Joseph D Khoury; C Cameron Yin
Journal: Curr Hematol Malig Rep Date: 2019-10 Impact factor: 3.952

5. Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2.

Authors: Constance Baer; Verena Muehlbacher; Wolfgang Kern; Claudia Haferlach; Torsten Haferlach
Journal: Haematologica Date: 2018-03-22 Impact factor: 9.941

6. The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic/myeloproliferative neoplasms.

Authors: Manja Meggendorfer; Sabine Jeromin; Claudia Haferlach; Wolfgang Kern; Torsten Haferlach
Journal: Haematologica Date: 2018-05 Impact factor: 9.941

7. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.

Authors: Laura Palomo; Manja Meggendorfer; Stephan Hutter; Sven Twardziok; Vera Ademà; Irene Fuhrmann; Francisco Fuster-Tormo; Blanca Xicoy; Lurdes Zamora; Pamela Acha; Cassandra M Kerr; Wolfgang Kern; Jaroslaw P Maciejewski; Francesc Solé; Claudia Haferlach; Torsten Haferlach
Journal: Blood Date: 2020-10-15 Impact factor: 22.113